Clinical Edge Journal Scan

Peritumoral injection of local anesthetic before BC surgery improves survival outcomes


 

Key clinical point: In patients with early, operable breast cancer (BC), peritumoral injection of a local anesthetic (lidocaine) prior to surgery improved survival outcomes.

Major finding: Peritumoral infiltration of lidocaine at the time of surgery led to 26% improvement in disease-free survival (hazard ratio [HR] 0.74; P = .017) and 29% improvement in overall survival (HR 0.71; P = .019) at a median follow-up of 68 months. No adverse events related to injection of lidocaine were reported.

Study details: Findings are from the phase 3 study including 1583 patients with early, operable BC who did not receive prior neoadjuvant treatment and were randomly assigned to undergo surgery with or without a peritumoral injection of 0.5% lidocaine 7-10 minutes preoperatively.

Disclosures: This study was supported by Department of Atomic Energy, India. Dr. Sudeep Gupta declared receiving research funding from several sources.

Source: Badwe RA et al. Effect of peritumoral infiltration of local anesthetic before surgery on survival in early breast cancer. J Clin Oncol. 2023 (Apr 6). Doi: 10.1200/JCO.22.01966

Recommended Reading

Commentary: Chemotherapies and gynecologic surgeries relative to breast cancer, April 2023
MDedge Hematology and Oncology
Breast conservation safe even with multiple-site tumors
MDedge Hematology and Oncology
‘Startling’ cost barriers after abnormal screening mammogram
MDedge Hematology and Oncology
De-escalation still beneficial after 10 years for some HER2+ breast cancers
MDedge Hematology and Oncology
Survival improved for some patients with metastatic cancers
MDedge Hematology and Oncology
Outpatient costs top drug costs in some insured, working women with breast cancer
MDedge Hematology and Oncology
AFib risk with cancer drugs underestimated
MDedge Hematology and Oncology
Insurers refusing MRI for women at high risk for breast cancer
MDedge Hematology and Oncology
Stage 0-II ER+ BC: Alternative exemestane dosing regimen noninferior to standard regimen
MDedge Hematology and Oncology
Breast-conserving surgery may benefit BC patients with multiple tumors in the same breast
MDedge Hematology and Oncology